Ages =< 50 years of age with chronic lymphocytic leukemia (CLL)
T-cell large granular lymphocytic leukemia
Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Lymphoma fulfilling the following criteria: Chemotherapy-sensitive (at least stable disease lymphomas that have failed at least 1 prior regimen of multi-agent chemotherapy and are INELIGIBLE for an autologous transplant. Patients with chronic lymphocytic leukemia (CLL) are not eligible regardless of disease status.
Group B: CD19+ B cell chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) undergoing allogeneic HSCT
Patient must have diagnosis of CLL that meets published 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute–sponsored Working Group (NCI-WG) criteria
Must have histologically or flow cytometry confirmed diagnosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) according to National Cancer Institute Working Group (NCI-WG) 1996 guidelines; the malignant B cells must co-express CD5 with CD19 or CD20; patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma; patients with CLL who have progressed on prior ibrutinib therapy will be eligible; patients with B-cell prolymphocytic leukemia and patients with Richter’s transformation of CLL/SLL are NOT eligible
Diagnosis of chronic lymphocytic leukemia (CLL) meeting criteria established in the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for the diagnosis and treatment of CLL
Ages =< 50 years with chronic lymphocytic leukemia (CLL)
No treatment indication according to IWCLL/NCI-WG (International Working Group in Chronic Lymphocytic Leukemia/National Cancer Institute-Working Group) 2008 criteria.
Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that meets IWCLL diagnostic criteria.
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute (NCI)-Working Group (WG) criteria, and relapsed after or refractory to at least 1 prior treatment
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or high-grade lymphomas (Burkitt’s lymphoma/lymphoblastic lymphoma)
Small lymphocytic lymphoma
Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with < 25% involvement by CLL/SLL cells
Chronic lymphocytic leukemia with high risk disease as defined by the European Society for Blood and Marrow Transplantation (EBMT) consensus criteria
Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following a minimum of two lines of standard therapy
Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL), confirmed by flow cytometry and as per the criteria outlined by the IWCLL/Hallek December 2008
Documented CD19+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Small lymphocytic lymphoma with absolute lymphocyte count <5x10E9/L at study entry
Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease, or chronic lymphocytic leukemia.
Histologically or cytologically confirmed Hodgkin and all NHL subtypes excluding Burkitt, chronic lymphocytic leukemia (CLL) and lymphoblastic lymphoma that is considered to have relapsed or to be refractory to primary chemotherapy
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Must have a confirmed diagnosis of CLL defined by 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Small lymphocytic lymphoma(SLL) with absolute lymphocyte count <5x10*9/L at study entry
Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease, or chronic lymphocytic leukemia
Indication for treatment as defined by the International Workshop in Chronic Lymphocytic Leukemia (IWCLL) Guidelines
Have documented chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) according to National Cancer Institute (NCI) criteria
Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair
Patients with small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) are excluded during the phase I portion of the study
Histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Patients with active chronic lymphocytic leukemia (CLL) disease requiring urgent chemotherapy
Low-grade non-Hodgkin lymphoma (including small lymphocytic lymphoma [SLL] and chronic lymphocytic leukemia [CLL]) or plasma cell neoplasm that has progressed after at least two prior therapies (excluding single agent rituximab and single agent steroids), or in the case of lymphoma undergone histologic conversion; patients with transformed lymphomas must have stable disease or better
Diagnosis of B-CLL, confirmed by flow cytometric analysis and as per the criteria outlined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/Hallek December 2008
Diagnosis of chronic lymphocytic leukemia with no history of previous treatments with monoclonal antibodies or chemotherapy.
Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia
Diagnosis of active CLL or SLL that meets at least 1 of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for requiring treatment
Diagnosis of chronic lymphocytic leukemia (CLL) meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders or International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
Patients with a history of CD19+ lymphoid malignancy defined as acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with active disease defined by presence of > 5% malignant blasts in bone marrow and/or peripheral blood, and/or minimal residual disease by flow cytometry or molecular analysis for fusion proteins, and/or positive imaging for extramedullary disease. Patients must have measurable disease at time of study treatment.
Histological confirmation of relapsed/refractory B-cell NHL, CD20+ \r\n* NOTE: patients with small lymphocytic lymphoma (SLL) are eligible however patients with chronic lymphocytic leukemia (CLL) are not eligible\r\n* Waldenstrom macroglobulinemia patients are not eligible; aggressive lymphoma patients who are transplant eligible must have undergone a transplant\r\n* The biopsy confirming relapse can be up to 24 weeks prior to registration as long as there is no intervening therapy
Known immunosuppressive disease, for example HIV infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL).
FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL):
Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any\n             histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI\n             criteria) (Reference Appendix C)
Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL)\r\n* Patients will be eligible in >= first complete remission (CR1) with molecularly negative disease\r\n* Patients in CR with molecularly positive disease or in PR will be excluded from autologous transplant
Pathologic diagnosis per local institutional review of Richter syndrome that transformed from chronic lymphocytic leukemia (CLL).
Chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL)
Diagnosis of Chronic Lymphocytic Leukemia (CLL) established according to International Workshop Chronic Lymphocytic Leukemia (IWCLL) criteria.
Known transformation of Chronic Lymphocytic Leukemia (CLL) to an aggressive B-cell malignancy at the time of screening
Cohort 4: Participants must have chronic lymphocytic leukemia.
Known immunosuppressive disease, for example HIV infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL)
Treatment naïve or previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
Subject who has high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma.
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
Patients must have histologically identified chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as defined by the World Health Organization (WHO) classification of hematopoietic neoplasms
Patients must have an indication for treatment by 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
Participants must have confirmed CLL/small lymphocytic lymphoma (SLL) relapsed after at least one prior therapy and currently in need of treatment by IWCLL 2008 criteria
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 10*9/L at the time of diagnosis and at study entry.
Chronic lymphocytic leukemia (CLL).
Histologically confirmed B-cell non-Hodgkin lymphoma (B-NHL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
Confirmed diagnosis of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)
CLL/SLL patients must have:\r\n* Indication for treatment according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria\r\n* Received at least one prior standard treatment regimen
Documented previously untreated CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria
Diagnosis of CLL per diagnostic criteria for relapsed or refractory CLL per the international workshop on chronic lymphocytic leukemia (iwCLL) guidelines
Documented CD19+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 109/L at the time of diagnosis and at study entry
Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease and chronic lymphocytic leukemia (CLL)
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets protocol-defined criteria
Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic Leukemia 2008 criteria for requiring treatment
Prior treatment for chronic lymphocytic leukemia.
Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma
Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), previously untreated, Rai stage 0-ll
Ages =< 50 years of age with chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia that has failed induction therapy or Rai stages 2-4
Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia [Hallek, 2008]).
Patients will have a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or cluster of differentiation (CD)20 positive low-grade lymphoproliferative disorder
Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following standard therapy; or
Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion of investigator
Patients with lymphoma (non-Hodgkin lymphoma [NHL], chronic lymphocytic leukemia/small lymphocytic lymphoma [CLL/SLL] or Hodgkin's lymphoma) with primary refractory or relapsed disease after standard chemotherapy at high risk of relapse with conventional autografting; patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL
Diagnosis of B-cell CLL, established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and having received at least 2 prior treatment regimens
Diagnosis of B-cell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 10^9/L at the time of diagnosis
Histologically confirmed Richter's transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Diagnosis of Chronic lymphocytic leukemia or Small lymphocytic lymphoma that meets at least one of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for treatment (Binet Stage ? B and/or Rai Stage ? I with symptoms)
History of chronic leukemias (eg, chronic lymphocytic leukemia).
Documented diagnosis of B-cell CLL, according to International Workshop on Chronic Lymphocytic Leukemia 2008
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
T cell large granular lymphocytic leukemia
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count
Patients with CD20-expressing B-cell NHL that is relapsed or refractory to standard therapy. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with peripheral blood leukemia/lymphoma cells and high-grade lymphomas are excluded
Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.
Chronic lymphocytic leukemia (CLL)
Low-grade non-Hodgkin’s lymphoma or plasma cell neoplasm with either of the following, and with stable disease or better prior to transplantation:\r\n* Progressed during multiagent therapy, failed at least two prior therapies (excluding single agent rituximab), or there is evidence of prior transformation\r\n* Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with 11q or 17p deletion or with progression < 6 months after a purine analog-containing regimen
At least two prior treatment regimens for chronic lymphocytic leukaemia.
CLL, Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma. Subjects suspicious for transformation should undergo a biopsy to exclude the possibility of transformation. Subjects with a previous diagnosis of small lymphocytic leukemia (SLL) and a screening monoclonal B-lymphocyte count of ? 5000/µl are defined by 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria to have CLL; such patients are NOT eligible for this study.
Small lymphocytic lymphoma (SLL)
Patients with chemo-sensitive chronic lymphocytic leukemia (CLL) with persistent or recurrent disease after fludarabine-based regimens, no evidence of \bulky\ disease (> 10 cm in diameter)
Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicular lymphoma
PHASE I: Histological confirmation of relapsed (recurrent after previous therapy[ies]) or refractory (no response to previous therapy[ies]) B-cell NHL; note: patients with small lymphocytic lymphoma (SLL) are eligible however patients with chronic lymphocytic leukemia (CLL) are not eligible
Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with 17p deletion, or with progression < 6 months after second or greater treatment regimen; must have the following to be an acceptable candidate as well:\r\n* =< 20% of bone marrow cellularity involved by SLL/CLL (to lower risk of graft rejection)\r\n* No lymph nodes >= 5 cm in any dimension\r\n* No massive splenomegaly, defined as > 6 cm below the left costal margin
Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma who are in remission or asymptomatic after initial treatment and are being followed with active surveillance will be eligible.
Prior exposure to ABT-199 or B-cell chronic lymphocytic leukemia (CLL)/lymphoma 2 (BCL2) inhibitors
Chronic lymphocytic leukemia (CLL) patients with IgG less than 500 mg/dl with/without symptoms who are either untreated or previously treated, regardless of response, at least 6 months from prior therapy (including monoclonal antibody [mAb])
Newly diagnosed aggressive lymphoma or CLL/small lymphocytic lymphoma (SLL) that meets disease specific criteria below:
Chronic lymphocytic leukemia (CLL).
Active cancer or metastatic disease, except in the case of stage 0 chronic lymphocytic leukemia or nonmelanoma skin cancer
No concurrent, active malignancy, other than non-metastatic skin cancer of any type, superficial bladder cancer, or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma) or < stage IV follicular lymphoma; if a prior malignancy is in remission for >= 3 years then the patient is eligible
Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per International Workshop on Chronic Lymphocytic Leukemia (IW-CLL) 2008 criteria with biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), consistent with Richter’s Syndrome
Food and Drug Administration (FDA)-approved indications for idelalisib of relapsed, histologically confirmed B-cell indolent non-Hodgkin lymphoma (iNHL) or chronic lymphocytic leukemia (CLL)
Patient has a diagnosis of chronic lymphocytic leukemia
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
Clinical evidence of transformation to a more aggressive subtype of lymphoma
Richter’s transformation confirmed by biopsy
Known histological transformation to an aggressive lymphoma
Active Richter’s transformation
History of Richter’s or prolymphocytic transformation
Known histological transformation to an aggressive lymphoma (ie, Richter transformation). Note: Biopsy documentation of the absence or presence of transformation is not required.
For patients with Richter’s transformation, one prior line of therapy for either CLL or Richter’s transformation (RT) is required
Grade 3B FL or evidence of transformation of FL to a more aggressive lymphoma
Patients with previously treated CLL and biopsy-proven Richter’s transformation with diffuse large B-cell lymphoma (DLBCL) histology according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (Richter Transformation - RT) and CD19 positive by flow cytometry OR immunohistochemistry.
Richter’s transformation confirmed by biopsy
Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL.
CLL patients with known or suspected transformed disease (i.e. Richter’s transformation)\r\n* Note: biopsy proven absence of transformation is not required
Large cell transformation
Evidence ongoing transformation into aggressive NHL
CLL patients with active transformed disease (Richter’s transformation) are ineligible for enrollment on this study
Known histological transformation from CLL to an aggressive lymphoma (Richter's)
Known histological transformation from iNHL or CLL to an aggressive form of non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL patient is enrolling in the B-cell receptor (BCR) previously treated cohort
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Patients must not have any history of Richter’s transformation or prolymphocytic leukemia (prolymphocytes in blood > 55%)
Evidence of disease transformation at the time of study entry
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Presence of more than 55% pro-lymphocytes in peripheral blood; patients with Richter’s transformation are not excluded
Evidence of diffuse large B-cell transformation
Active Richter’s transformation
Cohort B-4: 1) Histologically-confirmed Richter syndrome defined as transformation of CLL or SLL into an aggressive lymphoma 2) Previously treated with at least one line of standard, systemic chemotherapy or not eligible for standard therapy 3) At least 1 measurable site of disease based on the Revised Response Criteria for Malignant Lymphoma
Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Transformation of CLL to aggressive Non-Hodgkin's lymphoma (Richter's transformation or pro-lymphocytic leukemia)
Grade 1, 2, or 3a FL without pathologic evidence of transformation
Transformation of CLL to aggressive non-Hodgkin lymphoma or central nervous system (CNS) involvement by CLL
Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.
Presence of disease transformation from a previously diagnosed low-grade lymphoma
Evidence of diffuse large B-cell transformation.
Follicular lymphoma with histology documented by the participating institution (grades 1, 2 or 3a)\r\n* For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation
Subjects with known SCLC transformation
CLL transformation
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Prior radiotherapy is allowed if it was given for low-grade lymphoma before transformation in those with transformed NHL and as long as no chemotherapy was administered in conjunction with radiation
Transformation to a more aggressive subtype of lymphoma or grade 3b FL
Prolymphocytic transformation
Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
Patients with B-CLL (not in Richter’s transformation) with measurable disease
Patients with tMF who received 1 systemic single-agent CT (except methotrexate) prior to transformation.
Evidence of aggressive or highly aggressive lymphoma or Richter’s transformation based on WHO/REAL classification criteria(1)
Pathologic evidence of malignant transformation
FL with evidence of large cell transformation
Known transformation to an aggressive B-cell malignancy.
Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Patients with Richter’s transformation are not allowed in the study
Patients with the Hodgkin variant transformation of CLL will be excluded
Known histological transformation from iNHL to diffuse large B-cell lymphoma or Richter’s transformation for CLL
Richter's transformation or CLL transformation to aggressive lymphoma
History of Richter’s or prolymphocytic transformation
Histologically confirmed, biopsy-proven diagnosis of DLBCL, BCLu, HGBCL, or TiNHL. Richter's transformation from Chronic Lymphocytic Leukemia (CLL) is not eligible.
Richter's transformation from CLL
History of Richter's transformation from CLL
CLL WITH RICHTER's TRANSFORMATION (ARM C) ONLY
Presence of more than 55% pro-lymphocytes in peripheral blood; patients with Richter's transformation are not excluded
Richter's transformation confirmed by biopsy
Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)
Richter transformation.
Richter transformation
Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
Participants with CLL or DLBCL who have Richter's Transformation
Patients with active Richter's syndrome (>10% large B-cells in marrow).
Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)
History of Richter's transformation or prolymphocytic leukemia
Patients with known Richter's transformation which is progressive and is deemed to require immediate chemotherapy (history of Richter's transformation is not an exclusion); patients with prolymphocytic leukemia (prolymphocytes in blood >55%)
Diagnosis of CLL without the following: Richter's transformation, prolymphocytic leukemia (PLL), small lymphocytic lymphoma (SLL)
If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.
Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
Richter syndrome
Patients with chronic non-T-cell-based lymphocytic leukemia are eligible if they have isolated lymphocytosis (Rai stage O) on the condition that they do not require systemic treatment for their disease [\B\ symptoms, Richter's transformation, lymphocyte doubling time (<6 months) and they do not have lymphadenopathy of hepatosplenomegaly].
Subject has developed Richter's transformation confirmed by biopsy
Richter's Syndrome and Prolymphocytic Leukemia Transformation only: biopsy proven DLBCL Richter's transformation or prolymphocytic leukemia transformation.
History of Richter's transformation or prolymphocytic leukemia
Subjects with Richter's transformation
Known central nervous system leukemia/lymphoma or Richter's transformation
CLL patients with transformed disease (Richter's transformation) are ineligible for enrollment on this study
Disease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]
Disease transformation (active) (ie, Richter's Syndrome, prolymphocytic leukemia)
Richter's transformation or prolymphocytic leukemia
Richter's transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including large B-cell and immunoblastic variants.
Active disease transformation (ie, Richter's Syndrome); subjects with Richter's Syndrome that has resolved > 2 years from signing the ICD are eligible.
Co-existent diffuse large B-cell lymphoma (Richter's transformation)
Patients with chronic lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation who are eligible for allogeneic transplantation and are not eligible for protocols of higher priority.
Known transformation of CLL (e.g. Richter's).
Documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood) or Richter's transformation